The value of Orlistat combined with Metformin in the treatment of obese polycystic ovary syndrome
奥利司他联合二甲双胍治疗肥胖型多囊卵巢综合征的价值

摘要

目的 探究奥利司他联合二甲双胍治疗肥胖型多囊卵巢综合征的临床效果。方法 选取本院2022年1月-2023年1月期间收治的肥胖型多囊卵巢综合征患者74例，按照随机数字表法分配为对照组和观察组，每组37例。对照组采用奥利司他治疗，观察组用奥利司他联合二甲双胍治疗。对比两组患者治疗前后体重指数、胰岛素抵抗指数( Homa-IR)、用药三个月后妊娠率、早产率和流产率。结果 治疗后，观察组患者体重指数改善情况和Homa-IR指数、血清性激素水平优于对照组，差异有统计学意义（P＜0.05）；观察组患者妊娠率高于对照组，早产率和流产率低于对照组，差异有统计学意义（P＜0.05）。结论 奥利司他联合二甲双胍治疗肥胖型多囊卵巢综合征的临床效果显著，可明显改善患者胰岛素抵抗状态，改善妊娠结局，值得临床推广。

Abstract

Objective To explore the clinical effect of Orlistat combined with Metformin in the treatment of obese polycystic ovary syndrome.
Methods 74 patients with obese polycystic ovary syndrome admitted to our hospital from January 2022 to January 2023 were selected and randomly divided into a control group and an observation group, with 37 patients in each group. The control group was treated with Orlistat, and the observation group was treated with Orlistat combined with Metformin. Compare the body mass index, insulin resistance index (Home-IR), pregnancy rate, preterm birth rate, and miscarriage rate of two groups of patients before and after treatment.
Results After treatment, the improvement of body mass index, Home-IR index, and serum sex hormone levels in the observation group were better than those in the control group, with statistically significant differences (P<0.05); The pregnancy rate of the observation group was higher than that of the control group, while the premature birth rate and miscarriage rate were lower than those of the control group, with statistically significant differences (P<0.05).
Conclusion   Orlistat combined with Metformin has a significant clinical effect in the treatment of obese polycystic ovary syndrome, which can significantly improve the insulin resistance status of patients and improve the pregnancy outcome, and is worthy of clinical promotion.